

12 May 2025

PACIFIC EDGE FY25 RESULT TO BE ANNOUNCED 30 MAY 2025

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) advises that its full year results for the 12 months to 31 March 2025 (FY25) will be released on Friday 30 May 2025, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This investor briefing will be available via webcast by the following link: www.virtualmeeting.co.nz/pebfy25 or by phone on the following toll-free numbers:

New Zealand - Toll Free 0800 450 012
Australia - Toll Free 1800 571 226
USA & Canada - Toll-Free (800) 715 9871

Conference ID: 2639914

Questions

Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when prompted.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley on stacey.stanley@pelnz.com.

ENDS

Approved for release by:

Grant Gibson
Chief Financial Officer
Pacific Edge Ltd
P: 0800 555 563 (NZ)

OVERVIEW

Pacific Edge: www.pacifiedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.